FDANews

MEDIGENE'S DRUG ELIGARD LAUNCHED IN SPAIN AND FURTHER EUROPEAN COUNTRIES

The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) anounces the launch of its prostate cancer drug Eligard, in Spain. With a potential for sales in this indication of € 100 million, Spain is one of the largest markets in Europe for drugs of this category. Currently Eligard is available for patients and physicians in the following countries: Germany, Spain, Portugal, the Netherlands and Switzerland.

DG News (http://www.docguide.com/news/content.nsf/news/8525697700573E18852570BA004F8EAF)